Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy?

Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 (including dividend payments). Conversely, hedge funds’ 30 preferred S&P 500 stocks (as of June 2014) generated a return of 15.1% during the same 12-month period, with 53% of these stock picks outperforming the broader market benchmark. Coincidence? It might happen to be so, but it is unlikely. Our research covering the last 18 years indicates that hedge funds’ stock picks generate superior risk-adjusted returns. That’s why we believe it is wise to check hedge fund activity before you invest your time or your savings on a stock like Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH).

Is Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) going to take off soon? Hedge funds are in a pessimistic mood. The number of long hedge fund bets shrunk by 1 in recent months. Our calculations also showed that DCPH isn’t among the 30 most popular stocks among hedge funds.

If you’d ask most traders, hedge funds are viewed as underperforming, old financial vehicles of years past. While there are more than 8,000 funds trading at the moment, We choose to focus on the masters of this group, about 700 funds. It is estimated that this group of investors administer most of the hedge fund industry’s total asset base, and by shadowing their first-class picks, Insider Monkey has revealed several investment strategies that have historically outrun the S&P 500 index. Insider Monkey’s flagship hedge fund strategy outstripped the S&P 500 index by 6 percentage points per annum since its inception in May 2014 through early November 2018. We were able to generate large returns even by identifying short candidates. Our portfolio of short stocks lost 24% since February 2017 (through December 3rd) even though the market was up nearly 23% during the same period. We just shared a list of 11 short targets in our latest quarterly update.

Andreas Halvorsen

We’re going to take a look at the recent hedge fund action encompassing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH).

What have hedge funds been doing with Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)?

Heading into the fourth quarter of 2018, a total of 16 of the hedge funds tracked by Insider Monkey were long this stock, a change of -6% from one quarter earlier. By comparison, 12 hedge funds held shares or bullish call options in DCPH heading into this year. So, let’s examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

DCPH_dec2018

More specifically, OrbiMed Advisors was the largest shareholder of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), with a stake worth $75.6 million reported as of the end of September. Trailing OrbiMed Advisors was Redmile Group, which amassed a stake valued at $57.2 million. Polar Capital, Viking Global, and Opaleye Management were also very fond of the stock, giving the stock large weights in their portfolios.

Since Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has faced declining sentiment from hedge fund managers, we can see that there lies a certain “tier” of money managers that decided to sell off their positions entirely in the third quarter. Intriguingly, Zach Schreiber’s Point State Capital dropped the biggest investment of all the hedgies tracked by Insider Monkey, valued at close to $6.9 million in stock, and Leon Cooperman’s Omega Advisors was right behind this move, as the fund dumped about $4.7 million worth. These moves are interesting, as total hedge fund interest was cut by 1 funds in the third quarter.

Let’s go over hedge fund activity in other stocks similar to Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH). These stocks are Gibraltar Industries Inc (NASDAQ:ROCK), Helix Energy Solutions Group Inc. (NYSE:HLX), Herc Holdings Inc. (NYSE:HRI), and Natera Inc (NASDAQ:NTRA). This group of stocks’ market caps match DCPH’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
ROCK 12 124889 1
HLX 16 59869 -1
HRI 24 667633 1
NTRA 21 204485 7
Average 18.25 264219 2

View table here if you experience formatting issues.

As you can see these stocks had an average of 18.25 hedge funds with bullish positions and the average amount invested in these stocks was $264 million. That figure was $257 million in DCPH’s case. Herc Holdings Inc. (NYSE:HRI) is the most popular stock in this table. On the other hand Gibraltar Industries Inc (NASDAQ:ROCK) is the least popular one with only 12 bullish hedge fund positions. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. In this regard HRI might be a better candidate to consider a long position.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...